ArticleNature2021
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and T
Abstract readPublished Erratum
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects.Frontiers in immunology · 2022Pooled it
- Hepatic Metabolic Dysregulation as a Potential Amplifier of Leukemogenesis Following mRNA Vaccination: A Novel Mechanistic Hypothesis.Medicina (Kaunas, Lithuania) · 2025Article
- Research progress of mRNA vaccines for infectious diseases.European journal of medical research · 2025Review
- High-dimensional multi-pass flow cytometry via spectrally encoded cellular barcoding.Nature biomedical engineering · 2024Article
- Secure reversal of immune evasion from refractory NSCLC and highly contagious CoV-2 mutants by using 3D-engineered multifunctional biologics.Bioengineering & translational medicine · 2023Article
- Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity.Communications medicine · 2023Article
- Article
- Unravelling the role of individual components in pBAE/polynucleotide polyplexes in the synthesis of tailored carriers for specific applications: on the road to rational formulations.Nanoscale advances · 2023Article
- Specific antibody response of 14 patients with common variable immunodeficiency to 3 BNT162b2 messenger RNA coronavirus disease 2019 vaccinations.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2022Article
- Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy.Medical microbiology and immunology · 2022Review
- Immediate Hypersensitivity Reactions Induced by COVID-19 Vaccines: Current Trends, Potential Mechanisms and Prevention Strategies.Biomedicines · 2022Review
- Study of humoral and cellular immunity in vaccinated with mRNA-1273.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2022Article
- Advances in COVID-19 mRNA vaccine development.Signal transduction and targeted therapy · 2022Review
- The Relation between Immunological Features and the Positive SARS-CoV-2 Nucleic Acid in Patients with Nonsevere COVID⁃19.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2022Article
- Lichen planus flare following COVID-19 vaccination: A case report.Clinical case reports · 2021Article
- Nano-carriers of COVID-19 vaccines: the main pillars of efficacy.Nanomedicine (London, England) · 2021Review
- SARS-CoV-2 vaccination in solid-organ transplant recipients: What the clinician needs to know.Transplant international : official journal of the European Society for Organ Transplantation · 2021Review
- Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis.Journal of clinical medicine · 2021Review
Corrections and comments
- Erratum for
Authors and funding
42 authors.
Ugur SahinBioNTech, Mainz, Germany. ugur.sahin@biontech.de.ORCID http://orcid.org/0000-0003-0363-1564
Alexander MuikBioNTech, Mainz, Germany.ORCID http://orcid.org/0000-0003-4561-2273
Evelyna DerhovanessianBioNTech, Mainz, Germany.
Isabel VoglerBioNTech, Mainz, Germany.ORCID http://orcid.org/0000-0001-9757-9618
Lena M KranzBioNTech, Mainz, Germany.ORCID http://orcid.org/0000-0003-1943-3431
Mathias VormehrBioNTech, Mainz, Germany.ORCID http://orcid.org/0000-0001-7788-3380
Alina BaumRegeneron Pharmaceuticals, Tarrytown, NY, USA.
Kristen PascalRegeneron Pharmaceuticals, Tarrytown, NY, USA.ORCID http://orcid.org/0000-0003-4826-4606
Jasmin QuandtBioNTech, Mainz, Germany.ORCID http://orcid.org/0000-0001-9589-9941
Daniel MaurusBioNTech, Mainz, Germany.
Sebastian BrachtendorfBioNTech, Mainz, Germany.
Verena LörksBioNTech, Mainz, Germany.
Julian SikorskiBioNTech, Mainz, Germany.
Rolf HilkerBioNTech, Mainz, Germany.ORCID http://orcid.org/0000-0002-8576-7731
Dirk BeckerBioNTech, Mainz, Germany.
Ann-Kathrin EllerBioNTech, Mainz, Germany.
Jan GrütznerBioNTech, Mainz, Germany.
Carsten BoeslerBioNTech, Mainz, Germany.
Corinna RosenbaumBioNTech, Mainz, Germany.
Marie-Cristine KühnleBioNTech, Mainz, Germany.
Ulrich LuxemburgerBioNTech, Mainz, Germany.
Alexandra Kemmer-BrückBioNTech, Mainz, Germany.
David LangerBioNTech, Mainz, Germany.
Martin BexonBexon Clinical Consulting, Upper Montclair, NJ, USA.ORCID http://orcid.org/0000-0002-5361-4343
Stefanie BolteBioNTech, Mainz, Germany.
Katalin KarikóBioNTech, Mainz, Germany.ORCID http://orcid.org/0000-0002-1864-3851
Tania PalancheBioNTech, Mainz, Germany.
Boris FischerBioNTech, Mainz, Germany.
Armin SchultzCRS Clinical Research Services Mannheim GmbH, Mannheim, Germany.
Pei-Yong ShiUniversity of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0001-5553-1616
Camila Fontes-GarfiasUniversity of Texas Medical Branch, Galveston, TX, USA.
John L PerezPfizer, Pearl River, NY, USA.
Kena A SwansonPfizer, Pearl River, NY, USA.ORCID http://orcid.org/0000-0002-3389-8414
Jakob LoschkoPfizer, Pearl River, NY, USA.
Ingrid L ScullyPfizer, Pearl River, NY, USA.
Mark CutlerPfizer, Pearl River, NY, USA.
Warren KalinaPfizer, Pearl River, NY, USA.
Christos A KyratsousRegeneron Pharmaceuticals, Tarrytown, NY, USA.
David CooperPfizer, Pearl River, NY, USA.
Philip R DormitzerPfizer, Pearl River, NY, USA.
Kathrin U JansenPfizer, Pearl River, NY, USA.
Özlem TüreciBioNTech, Mainz, Germany.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
PMID
33469214What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.